福安药业10月15日获融资买入812.79万元，融资余额4.20亿元

Core Viewpoint - Fu'an Pharmaceutical experienced a stock price increase of 1.38% on October 15, with a trading volume of 67.58 million yuan, indicating a positive market sentiment despite a net financing outflow [1] Financing Summary - On October 15, Fu'an Pharmaceutical had a financing buy-in amount of 8.13 million yuan and a financing repayment of 13.28 million yuan, resulting in a net financing outflow of 5.15 million yuan [1] - The total financing and securities balance for Fu'an Pharmaceutical reached 420 million yuan, accounting for 7.98% of its circulating market value, which is above the 80th percentile of the past year [1] - The company had no shares sold or repaid in the securities lending market on October 15, with a remaining securities lending balance of 1,326 yuan, indicating a high level of securities lending activity [1] Business Performance Summary - As of September 30, Fu'an Pharmaceutical had 39,000 shareholders, a decrease of 0.44% from the previous period, while the average circulating shares per person increased by 0.44% to 24,824 shares [2] - For the first half of 2025, Fu'an Pharmaceutical reported a revenue of 921 million yuan, a year-on-year decrease of 35.76%, and a net profit attributable to shareholders of 113 million yuan, down 47.74% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 688 million yuan in dividends, with 202 million yuan distributed over the past three years [2] Shareholding Summary - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh largest circulating shareholder of Fu'an Pharmaceutical, holding 5.45 million shares, a decrease of 5.04 million shares from the previous period [2]